6th Conference on Retroviruses and Opportunistic Infections Chicago, IL - January 31-February 4, 1999

Conf Retroviruses Opportunistic Infect 1999 Jan 31-Feb 4; 6th:70 (abstract no. 17)

Amado R, Rosenblatt J, Zack J, Reier A, Ely J, Symonds G, Mitsuyasu R
6 to 10(7) cells/kg, with a purity of 65% to 84%. Transduction of CFU was achieved at a range of 7%-17% in the first 3 pts (assessed by G418 resistance and single colony PCR). Transduction in the presence of fragment CH-296 of fibronectin increased this to 33% in a subsequent pt. No adverse events were observed in any pt with a median follow up of 3 mos. No significant changes in viral load or CD4 counts were observed in this period. In 4 pts followed to 12 wks, vector marked cells were detectable in the bone marrow and peripheral blood granulocytes. T cells and monocytes at wks 4 and 12. These data indicate the feasibility of a gene therapy approach to the treatment of HIV infection. Longer-term follow up is needed to establish whether the ribozyme-bearing cells exhibit a selective survival advantage.

Keywords: AEGIS, Antigens, CD34, RNA, Catalytic, Gene Therapy, HIV-1, HIV Infections, Genetic Vectors, CD4 Lymphocyte Count, Monocytes, Viral Load, T-Lymphocytes, Granulocyte Colony-Stimulating Factor, Human, AIDS

1999-01-31
17

Copyright © 1999 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.